A series of preclinical and early research updates pointed to mechanism-driven oncology hypotheses. Researchers described how colorectal cancer cells can hijack interferon beta signaling through MEK pathways to enter a dormant, death-evading state resistant to chemotherapy and immunotherapy, published in the Journal of Experimental & Clinical Cancer Research. In lung cancer biology, a study identified ZUP1 as a crossroad between cisplatin resistance and Treg signaling, linking DNA-damage repair and immune suppression cues—an intersection that could support combination strategies or biomarker-driven patient selection. While these are not regulatory milestones, both findings sharpen the map of resistance biology and reinforce the push toward targeting therapy escape mechanisms that occur across tumor and immune compartments.